Omnicell (OMCL)
(Delayed Data from NSDQ)
$29.31 USD
+0.02 (0.07%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $29.55 +0.24 (0.82%) 7:58 PM ET
4-Sell of 5 4
B Value D Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$29.31 USD
+0.02 (0.07%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $29.55 +0.24 (0.82%) 7:58 PM ET
4-Sell of 5 4
B Value D Growth F Momentum C VGM
Zacks News
Here's Why You Should Invest in AMN Healthcare (AMN) Stock Now
by Zacks Equity Research
AMN Healthcare (AMN) continues to benefit from its broad range of services.
Zacks Industry Outlook Highlights Omnicell, Axonics and Outset Medical
by Zacks Equity Research
Omnicell, Axonics and Outset Medical have been highlighted in this Industry Outlook article.
3 Reasons to Retain Nevro (NVRO) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Nevro (NVRO) owing to its strength in the global SCS market.
Change Healthcare (CHNG)-Luma Launch Patient Engagement Suite
by Zacks Equity Research
Change Healthcare's (CHNG) latest launch is expected to significantly improve patients' healthcare journey and create a more streamlined patient experience.
3 Medical Info System Stocks Braving Industry Headwinds
by Urmimala Biswas
Medical Info Systems stocks like Omnicell, Inc. (OMCL), Axonics, Inc. (AXNX) and Outset Medical, Inc. (OM) are expected to gain despite pandemic-led disruptions.
Should Vanguard S&P SmallCap 600 Growth ETF (VIOG) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VIOG
Here's Why You Should Hold on to Inogen (INGN) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Inogen (INGN) on its potential in the POC space and a strong product portfolio.
Veeva Systems (VEEV) Inks Deal to Serve Rare Disease Patients
by Zacks Equity Research
Adoption of Veeva Systems' (VEEV) cloud applications is likely to significantly boost its Veeva Development Cloud business.
Should SPDR Portfolio S&P 600 Small Cap ETF (SPSM) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SPSM
Here's Why You Should Hold on to DaVita (DVA) Stock For Now
by Zacks Equity Research
Investors remain optimistic about DaVita (DVA) due to strength in its DaVita Kidney Care and impressive overseas growth.
Privia Health (PRVA) Surges 8.1%: Is This an Indication of Further Gains?
by Zacks Equity Research
Privia Health (PRVA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Here's Why You Should Hold on to Abiomed (ABMD) Stock For Now
by Zacks Equity Research
Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.
Here's Why You Should Hold on to Surmodics (SRDX) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Surmodics (SRDX) owing to its consistent efforts to boost R&D.
Anthem (ANTM) Unveils Two Brands to Boost Whole Person Health
by Zacks Equity Research
Anthem (ANTM) launches Carelon and Wellpoint brands to streamline its products and services portfolio as well as bring about enhanced health plans for clients and consumers.
West Pharmaceutical's (WST) Syringe System to Improve Outcome
by Zacks Equity Research
West Pharmaceutical's (WST) new CZ syringe system size is expected to enable a simpler patient experience and aid pharmaceutical companies in providing better access to their products.
BD's (BDX) Latest Collaboration to Enhance Patient Care
by Zacks Equity Research
BD's (BDX) new partnership is expected to increase efficiency for new clinical trials, generate evidence, support new claims for its products and streamline medical device regulatory submissions.
Here's Why You Should Hold on to Ecolab (ECL) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Ecolab (ECL) owing to its solid product portfolio.
CPSI vs. OMCL: Which Stock Is the Better Value Option?
by Zacks Equity Research
CPSI vs. OMCL: Which Stock Is the Better Value Option?
Here's Why Investors Should Retain Omnicell (OMCL) Stock Now
by Zacks Equity Research
Investors are optimistic about Omnicell's (OMCL) better-than-expected results and new launches.
Should SPDR S&P 600 Small Cap ETF (SLY) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SLY
Should iShares Core S&P SmallCap ETF (IJR) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IJR
Should Vanguard S&P SmallCap 600 ETF (VIOO) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VIOO
Catalent's (CTLT) Latest Facility Expansion to Boost Capacity
by Zacks Equity Research
Catalent's (CTLT) latest site expansion is expected to significantly boost its business.
Reasons to Retain Catalent (CTLT) Stock in Your Portfolio
by Zacks Equity Research
Catalent's (CTLT) robust facility expansion activities and a slew of strategic deals raise optimism on the stock.
What's in the Cards for Medtronic (MDT) in Q4 Earnings?
by Zacks Equity Research
Medtronic's (MDT) Cardiovascular business is expected to have gained share in both high and low power devices in Q4.